Drug Interactions and the Cytochrome P450 System: The Role of Cytochrome P450 1A2

Kim Brøsen*

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Cytochrome P450 1A2 (CYP1A2) accounts for about 10 to 15% of the total CYP content of human liver and is the major enzyme involved in the metabolism of imipramine, propranolol, clozapine, theophylline, and caffeine. It is also involved in the conversion of heterocyclic amines to their proximal carcinogenic and mutagenic forms, as well as in the metabolism of endogenous substances, including 17β-estradiol and uroporphyrinogen III. Fluvoxamine is a potent inhibitor of CYP1A2, and there is potential for interaction with drugs that are metabolised by this isoenzyme. This property of fluvoxamine may be usefully applied to identifying agents that are substrates of CYP1A2, and it has a possible therapeutic application in the prevention of CYP1A2-mediated toxic metabolite formation.

OriginalsprogEngelsk
TidsskriftClinical Pharmacokinetics
Vol/bind29
Udgave nummer1
Sider (fra-til)20-25
Antal sider6
ISSN0312-5963
DOI
StatusUdgivet - 1. jan. 1995

Fingeraftryk

Cytochrome P-450 CYP1A2
Drug Interactions
Cytochrome P-450 Enzyme System
Fluvoxamine
Uroporphyrinogens
Imipramine
Clozapine
Poisons
Propranolol
Isoenzymes
Amines
Liver
Enzymes

Citer dette

@article{77ca62f06c364721a1698f3b22da68ec,
title = "Drug Interactions and the Cytochrome P450 System: The Role of Cytochrome P450 1A2",
abstract = "Cytochrome P450 1A2 (CYP1A2) accounts for about 10 to 15{\%} of the total CYP content of human liver and is the major enzyme involved in the metabolism of imipramine, propranolol, clozapine, theophylline, and caffeine. It is also involved in the conversion of heterocyclic amines to their proximal carcinogenic and mutagenic forms, as well as in the metabolism of endogenous substances, including 17β-estradiol and uroporphyrinogen III. Fluvoxamine is a potent inhibitor of CYP1A2, and there is potential for interaction with drugs that are metabolised by this isoenzyme. This property of fluvoxamine may be usefully applied to identifying agents that are substrates of CYP1A2, and it has a possible therapeutic application in the prevention of CYP1A2-mediated toxic metabolite formation.",
author = "Kim Br{\o}sen",
year = "1995",
month = "1",
day = "1",
doi = "10.2165/00003088-199500291-00005",
language = "English",
volume = "29",
pages = "20--25",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd.",
number = "1",

}

Drug Interactions and the Cytochrome P450 System : The Role of Cytochrome P450 1A2. / Brøsen, Kim.

I: Clinical Pharmacokinetics, Bind 29, Nr. 1, 01.01.1995, s. 20-25.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Drug Interactions and the Cytochrome P450 System

T2 - The Role of Cytochrome P450 1A2

AU - Brøsen, Kim

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Cytochrome P450 1A2 (CYP1A2) accounts for about 10 to 15% of the total CYP content of human liver and is the major enzyme involved in the metabolism of imipramine, propranolol, clozapine, theophylline, and caffeine. It is also involved in the conversion of heterocyclic amines to their proximal carcinogenic and mutagenic forms, as well as in the metabolism of endogenous substances, including 17β-estradiol and uroporphyrinogen III. Fluvoxamine is a potent inhibitor of CYP1A2, and there is potential for interaction with drugs that are metabolised by this isoenzyme. This property of fluvoxamine may be usefully applied to identifying agents that are substrates of CYP1A2, and it has a possible therapeutic application in the prevention of CYP1A2-mediated toxic metabolite formation.

AB - Cytochrome P450 1A2 (CYP1A2) accounts for about 10 to 15% of the total CYP content of human liver and is the major enzyme involved in the metabolism of imipramine, propranolol, clozapine, theophylline, and caffeine. It is also involved in the conversion of heterocyclic amines to their proximal carcinogenic and mutagenic forms, as well as in the metabolism of endogenous substances, including 17β-estradiol and uroporphyrinogen III. Fluvoxamine is a potent inhibitor of CYP1A2, and there is potential for interaction with drugs that are metabolised by this isoenzyme. This property of fluvoxamine may be usefully applied to identifying agents that are substrates of CYP1A2, and it has a possible therapeutic application in the prevention of CYP1A2-mediated toxic metabolite formation.

UR - http://www.scopus.com/inward/record.url?scp=0029145903&partnerID=8YFLogxK

U2 - 10.2165/00003088-199500291-00005

DO - 10.2165/00003088-199500291-00005

M3 - Journal article

C2 - 8846619

AN - SCOPUS:0029145903

VL - 29

SP - 20

EP - 25

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 1

ER -